The American kratom industry, a billion-dollar market that emerged from a successful 2016 grassroots campaign against federal prohibition, is currently facing an internal schism that threatens its legal standing and public image. At the heart of this conflict is 7-hydroxymitragynine, commonly known as 7-OH, an ultra-potent alkaloid derived from the kratom plant (Mitragyna speciosa). While kratom advocates once stood united against the Drug Enforcement Administration (DEA), they are now sharply divided, with veteran lobbyists calling for a ban on concentrated 7-OH products while a new faction of manufacturers fights to keep the substance on the shelves of gas stations and specialty shops across the United States.
The Evolution of the Kratom Market: From Leaf to Laboratory
Kratom has been used for centuries in Southeast Asia, where laborers chewed the raw leaves for a mild stimulant effect or brewed them into tea for pain relief and relaxation. When the plant gained popularity in the U.S. during the early 2010s, it was marketed primarily as a natural, safer alternative to opioid painkillers. The primary active alkaloid in the plant is mitragynine, which typically constitutes about 1% to 2% of the dried leaf material.
In contrast, 7-hydroxymitragynine occurs naturally in only trace amounts—often less than 0.01% of the plant’s chemical makeup. However, modern extraction techniques have allowed manufacturers to isolate and concentrate 7-OH, creating products where it is the dominant active ingredient. Scientists have found that 7-OH is significantly more potent than mitragynine, acting as a more powerful agonist at the mu-opioid receptors in the brain. This pharmacological profile has led critics, including some within the kratom industry itself, to label 7-OH as a "chemically manipulated" opioid rather than a traditional herbal supplement.
The proliferation of these concentrates has been rapid. Over the past three years, brands such as Magic 7OH, 7 O’Heaven, and Pure OHMS have moved from niche online vendors to thousands of convenience stores. These products, often sold as flavored gummies, liquid shots, or capsules, promise intense pain relief and euphoria, drawing the attention of both consumers seeking alternatives to prescription narcotics and federal regulators concerned about public safety.
A Chronology of Conflict: From DEA Defiance to Internal Fracturing
To understand the current tension, one must look back at the landmark regulatory battle of 2016. In August of that year, the DEA announced its intent to place kratom into Schedule I of the Controlled Substances Act, a category reserved for drugs with no accepted medical use and a high potential for abuse, such as heroin and LSD.
The response was unprecedented. A coalition of users, veterans, and advocacy groups like the American Kratom Association (AKA) organized a massive lobbying effort. They secured support from a bipartisan group of lawmakers, ranging from progressive Senator Bernie Sanders to libertarian-leaning Senator Rand Paul. Under immense public and political pressure, the DEA took the rare step of withdrawing its notice of intent, allowing kratom to remain legal at the federal level.
However, the peace was short-lived. As the industry matured, the focus shifted from raw leaf powder to high-potency extracts. By 2023, the AKA began to distance itself from the emerging 7-OH market. Mac Haddow, the senior public policy fellow at the AKA, has become one of the most vocal critics of the substance, arguing that 7-OH products "masquerade as kratom" and threaten to undo a decade of advocacy work.
By mid-2024, the conflict reached a boiling point. In July, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. characterized the 7-OH industry as "sinister" during a press briefing. This was followed by a call from FDA Commissioner Marty Makary for the DEA to revisit scheduling, specifically targeting 7-OH. The timeline of 2025 and early 2026 shows a rapid acceleration of state-level bans, as local governments grew impatient with the lack of federal oversight.
Political Alliances and Conflicting Directives
The regulatory landscape has been further complicated by mixed signals from the highest levels of government. On May 11, 2025, President Donald Trump delivered remarks from the Oval Office that appeared to endorse "natural 7-OH." These comments were met with confusion by both scientists and policy experts, as 7-OH in commercial quantities is almost always the result of laboratory synthesis or intense chemical concentration, rather than "natural" occurrence in the leaf.
Adding to the complexity are the deep-seated political ties within the industry. Reports have surfaced suggesting that both RFK Jr. and Department of Homeland Security (DHS) Secretary Markwayne Mullin maintain connections with a prominent kratom lobbyist who has a past criminal conviction and ties to a major kratom beverage company. These relationships have led to accusations of "crony capitalism," with critics suggesting that established kratom players are using their political influence to crush 7-OH competitors under the guise of public safety.
Meanwhile, the 7-OH industry has begun to organize its own defense. The 7-HOPE Alliance, an advocacy group representing extract manufacturers, argues that 7-OH is an essential component of the kratom experience. Michele Ross, the group’s chief scientific adviser, testified before Colorado legislators in April 2025, asserting that separating 7-OH from kratom is logically inconsistent. "To say 7-OH is not kratom is to say caffeine is not coffee," Ross stated, emphasizing the substance’s value as an analgesic.
Scientific Concerns and Public Health Data
While the political battle rages, researchers are raising alarms about the safety profile of 7-OH concentrates. Chris McCurdy, a leading kratom researcher at the University of Florida, has noted that many products labeled as 7-OH contain poorly understood compounds. Because these extracts are often produced in unregulated laboratories, they may contain residual solvents or unintended chemical byproducts.
Data regarding 7-OH’s impact on human health is still emerging, but early reports are concerning. There have been documented cases of polydrug overdoses involving 7-OH, and a growing number of users are reporting severe withdrawal symptoms. On online forums such as Reddit, communities dedicated to 7-OH use are filled with accounts of "excruciating" detox periods, with some users seeking professional rehabilitation to break their dependency.
In California, health officials linked six fatal overdoses to 7-OH in late 2025, though in most cases, other substances were also present. These incidents have fueled the narrative that 7-OH represents a "new wave" of the opioid crisis, distinct from the traditional use of kratom leaf powder.
The Legislative Response: A Patchwork of Bans
In the absence of a clear federal mandate, individual states have taken the lead in regulating or banning 7-OH. As of early 2026, a dozen states—including Vermont and California—have moved to prohibit the sale of 7-OH products. The legal status of kratom itself remains a patchwork; while some states have banned the plant entirely, others have passed the Kratom Consumer Protection Act (KCPA), which sets age limits and purity standards but often does not specifically address high-potency 7-OH extracts.
Rhode Island provides a unique case study in this evolving legal environment. After years of a total kratom ban, the state recently overturned its prohibition, opting instead for a regulatory framework. However, even in states with progressive kratom laws, 7-OH remains a sticking point, with many legislators considering separate, more restrictive rules for extracts.
Broader Implications for the Future of Kratom
The battle over 7-OH is more than a dispute over a single chemical; it is a fight for the soul and the survival of the kratom industry. For the AKA and its allies, 7-OH is a liability that provides the FDA and DEA with the "smoking gun" they need to ban the entire plant. By advocating for a ban on 7-OH, they hope to preserve the legality of the raw leaf and traditional extracts.
For the 7-OH manufacturers, the issue is one of consumer choice and innovation. They argue that for individuals with chronic, debilitating pain, traditional kratom leaf is often insufficient, and that concentrated 7-OH provides a necessary pharmaceutical-grade alternative to more dangerous synthetic opioids like fentanyl.
As the DEA continues to monitor the situation, the outcome of this internal industry war will likely determine the federal government’s next move. If 7-OH continues to be linked to adverse health outcomes and overdoses, the "billion-dollar industry" built on the back of the 2016 victory may find itself facing a total shutdown. The coming months of 2026 will be a decisive period for lawmakers, scientists, and the millions of Americans who rely on kratom products, as they navigate the fine line between herbal supplement and potent opioid.
